ALX Oncology Holdings Inc. (NASDAQ:ALXO) Insider Sells $17,057.68 in Stock

ALX Oncology Holdings Inc. (NASDAQ:ALXO) insider Jaume Pons sold 10,796 shares of the firm’s stock in a transaction dated Monday, December 30th. The shares were sold at an average price of $1.58, for a total value of $17,057.68. Following the transaction, the insider now owns 580,714 shares of the company’s stock, valued at $917,528.12. This trade represents a 1.83 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

ALX Oncology Stock Down 6.6 %

Shares of ALXO traded down $0.11 during midday trading on Thursday, reaching $1.56. The stock had a trading volume of 759,703 shares, compared to its average volume of 830,562. The company has a market cap of $82.28 million, a price-to-earnings ratio of -0.52 and a beta of 1.04. The company’s fifty day simple moving average is $1.52 and its two-hundred day simple moving average is $2.90. The company has a debt-to-equity ratio of 0.07, a current ratio of 4.82 and a quick ratio of 4.82. ALX Oncology Holdings Inc. has a 1-year low of $1.19 and a 1-year high of $17.83.

Institutional Trading of ALX Oncology

A number of institutional investors have recently bought and sold shares of the business. Marshall Wace LLP raised its holdings in ALX Oncology by 423.0% during the second quarter. Marshall Wace LLP now owns 635,679 shares of the company’s stock worth $3,833,000 after purchasing an additional 514,133 shares in the last quarter. XTX Topco Ltd purchased a new stake in ALX Oncology in the third quarter valued at $578,000. Point72 Asset Management L.P. acquired a new position in ALX Oncology in the second quarter valued at $1,834,000. Los Angeles Capital Management LLC purchased a new position in shares of ALX Oncology during the third quarter worth about $469,000. Finally, Renaissance Technologies LLC increased its position in shares of ALX Oncology by 87.2% during the second quarter. Renaissance Technologies LLC now owns 438,200 shares of the company’s stock worth $2,642,000 after purchasing an additional 204,100 shares in the last quarter. 97.97% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on ALXO shares. HC Wainwright reissued a “buy” rating and issued a $25.00 price target on shares of ALX Oncology in a research report on Wednesday, December 18th. Jefferies Financial Group lowered ALX Oncology from a “buy” rating to a “hold” rating and decreased their target price for the company from $12.00 to $2.00 in a report on Thursday, December 19th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of ALX Oncology in a report on Wednesday, December 18th. Three research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to data from MarketBeat.com, ALX Oncology has a consensus rating of “Moderate Buy” and a consensus target price of $8.50.

ALX Oncology Company Profile

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.